Wells Fargo initiated coverage of Centessa (CNTA) with an Overweight rating and $31 price target Near-term OX2R, orexin-2 receptor, agonism data in narcolepsy type-1,2, and idiopathic hypersomnia, or IH, offer meaningful catalysts for Centessa, the analyst tells investors in a research note. The company’s NT2/IH data expected this year should have a greater capacity to re-rate shares, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Centessa resumed with an Outperform at Oppenheimer
- Buy Rating on Centessa Pharmaceuticals Driven by Promising Drug Candidates and Strong Financial Position
- Centessa Pharmaceuticals: Buy Rating Driven by ORX750’s Promising Efficacy and Acquisition Potential
- Centessa Pharmaceuticals: Promising Pipeline Developments and Strategic Flexibility Drive Buy Rating